Cognition Therapeutics Inc (CGTX)

Currency in USD
0.667
+0.082(+14.00%)
Closed·
After Hours
0.685+0.018(+2.64%)
·
CGTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
Fair Value
Day's Range
0.5560.700
52 wk Range
0.2221.290
Key Statistics
Prev. Close
0.586
Open
0.556
Day's Range
0.556-0.7
52 wk Range
0.222-1.29
Volume
4.09M
Average Volume (3m)
7.49M
1-Year Change
-8.45%
Book Value / Share
0.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CGTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.250
Upside
+387.26%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cognition Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Cognition Therapeutics Inc Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Cognition Therapeutics Inc Earnings Call Summary for Q4/2024

  • Net loss of $34M for 2024, unchanged from 2023 at $0.86 per share; stock stable at $0.45 in premarket trading
  • Strategic focus on Alzheimer's and DLB programs; discontinuing other projects to optimize resource allocation
  • $12.8M raised through ATM facility, extending cash runway into Q4 2025; $25M cash on hand as of Dec 31, 2024
  • Preparing for potential Phase III trials in Alzheimer's and DLB; exploring lower dose levels in future studies
  • Confident in regaining NASDAQ compliance by September 2025; seeking non-dilutive funding through partnerships
Last Updated: 20/03/2025, 13:52
Read Full Transcript

Compare CGTX to Peers and Sector

Metrics to compare
CGTX
Peers
Sector
Relationship
P/E Ratio
−1.2x−3.1x−0.5x
PEG Ratio
−0.060.020.00
Price/Book
3.4x3.4x2.6x
Price / LTM Sales
-2.2x3.3x
Upside (Analyst Target)
-98.2%45.1%
Fair Value Upside
Unlock22.0%7.4%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.250
(+387.26% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.14 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CGTX Income Statement

People Also Watch

0.92
KLTO
-4.15%
31.68
BMNR
-8.55%
2.100
VOR
+1.45%
0.386
IXHL
-34.02%
7.570
TRON
-10.73%

FAQ

What Stock Exchange Does Cognition Therapeutics Trade On?

Cognition Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cognition Therapeutics?

The stock symbol for Cognition Therapeutics is "CGTX."

What Is the Cognition Therapeutics Market Cap?

As of today, Cognition Therapeutics market cap is 41.37M.

What Is Cognition Therapeutics's Earnings Per Share (TTM)?

The Cognition Therapeutics EPS (TTM) is -0.71.

When Is the Next Cognition Therapeutics Earnings Date?

Cognition Therapeutics will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is CGTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Cognition Therapeutics Stock Split?

Cognition Therapeutics has split 0 times.

How Many Employees Does Cognition Therapeutics Have?

Cognition Therapeutics has 27 employees.

What is the current trading status of Cognition Therapeutics (CGTX)?

As of 04 Aug 2025, Cognition Therapeutics (CGTX) is trading at a price of 0.67, with a previous close of 0.59. The stock has fluctuated within a day range of 0.56 to 0.70, while its 52-week range spans from 0.22 to 1.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.